Jeffrey P. Hodge

Suggest Changes
Learn More
To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients(More)
Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro.(More)
INTRODUCTION New treatment options are needed for second-line therapy in patients with NSCLC. PATIENTS AND METHODS This was a phase Ib/II study in patients with nonsquamous NSCLC in whom 1 previous(More)